1 / 19

March 16, 2013 Beth Faiman, PhDc, MSN, APRN, BC, AOCN®

Managing the adverse events due to molecularly targeted therapies : Cardiovascular and Pulmonary Side Effects . March 16, 2013 Beth Faiman, PhDc, MSN, APRN, BC, AOCN® Nurse Practitioner, Cleveland Clinic Taussig Cancer Institute PhD Candidate, Case Western Reserve University Cleveland, Ohio.

radha
Download Presentation

March 16, 2013 Beth Faiman, PhDc, MSN, APRN, BC, AOCN®

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Managing the adverse events due to molecularly targeted therapies: Cardiovascular and Pulmonary Side Effects March 16, 2013 Beth Faiman, PhDc, MSN, APRN, BC, AOCN® Nurse Practitioner, Cleveland Clinic Taussig Cancer Institute PhD Candidate, Case Western Reserve University Cleveland, Ohio

  2. Molecularly Targeted Therapies (MTTs) • Small-molecule drugs • act on targets inside the cell • Monoclonal antibodies • cannot penetrate the cell’s plasma membrane and are directed against targets that are outside cells or on the cell surface Molecularly Targeted Therapies March 16, 2013 l 2

  3. Molecularly Targeted Therapies (Randomly Selected From MANY….) Information from: http://www.cancer.gov/cancertopics/factsheet/Therapy/targeted ; MoAb= Monoclonal Antibody; Her2=human epidermal growth factor receptor 2; GIST= gastrointestinal stromal tumor ; pancreatic neuroendocrine tumor; NSCLCA = non small cell lung cancer; PNET; VEGF=Vascular Endothelial Growth Factor Molecularly Targeted Therapies March 16, 2013 l 3

  4. Molecular Targeted Therapies (MTT) and Cardiotoxicity • Cardiotoxicity • a general term to describe a broad range of adverse effects on heart function induced by therapeutic molecules. • MTT-induced cardiovascular side effects include • left ventricular systolic dysfunction • heart failure • conduction abnormalities • acute coronary syndrome, and • hypertension • Angiogenic inhibitors can cause QT prolongation with the risk of torsades de pointe and sudden death • If a cancer is incurable, the risk of cardiotoxicity will often outweigh the safety risk Molecularly Targeted Therapies March 16, 2013 l 4 Ederhy S, Izzedine H, Massard C, et al, 2011;80(3):369-379.

  5. Molecular targeted therapies (MTT) and cardiotoxicity • Kinase-targeting agents can affect cardiac function • sunitinib, imatinib, dasatinib, trastuzumab, and sorafenib • There is an overlap of signaling pathways targeted in tumor growth and important in maintaining cardiac homeostasis Mellor et al 2011; Motzer et al., 2007; Seidman et al.,2002; Brave et al., 2008; Escudier et al., 2009; Llovet et al., 2008 Molecularly Targeted Therapies March 16, 2013 l 5

  6. Is Hypertension a Good Thing and Should We Treat It? • Treatment with angiogenesis inhibitors (either antibodies or TKIs that target VEGF) can cause life-threatening HTN • Poorly controlled hypertension can: • lead to cardiovascular events • renal disease • stroke • necessitate discontinuation of anti-cancer therapy Ederhy et al; Copur MS, Obermiller A. An Algorithm for the Management of Hypertension in the Setting of Vascular Endothelial Growth Factor Signaling Inhibition. Clinical Colorectal Cancer. 2011;10(3):151-156. Molecularly Targeted Therapies March 16, 2013 l 6

  7. Is Hypertension a Good Thing and Should We Treat It? • BP is regulated by cardiac output and blood volume regulation through baroreceptors in the kidneys and the vasculature • No specific recommendations for drug treatment of HTN • Maintain BP < 140/90 mmHg. • Discontinuation of anti-angiogenic treatment may be applicable if systolic BP is >200mmHg or diastolic BP > 100mmHg or in case of a hypertensive crisis. Ederhy et al, 2011; Syrigos K, Karapanagiotou E, Boura P, Manegold C, Harrington K. Bevacizumab-Induced Hypertension. BioDrugs. 2011/06/01 2011;25(3):159-169. Molecularly Targeted Therapies March 16, 2013 l 7

  8. Yes We Should Treat Hypertension! • Recommendations: American Heart Association and American College of Cardiology guidelines for the treatment of heart failure or of patients at high risk of heart failure • Beta Blockers (metoprolol, carvedilol, atenolol) • Angiotensin Converting Enzyme (ACE) Inhibitors (e.g. lisinopril, enalapril, ramipril) • Medications that interfere with cytochrome P450 and inhibitors of CYP3A4 (e.g. diltiazem, verapamil) should be avoided • Many oral anti-angiogenic agents are also cytochrome substrates Molecularly Targeted Therapies March 16, 2013 l 8 Jessup M, et al. (2009) Circulation. 119(14):1977-2016; Ederhy et al, 2011

  9. How serious is Q-T interval prolongation? • Q-T interval prolongation increases the risk of fatal arrhythmia • can be induced by several novel anti-cancer therapies. • Torsades de pointes and Ventricular fibrillation • Torsades is a characteristic illusion of a twisting of the QRS complex around the isoelectric baseline • Predispose the patient to an “R-on-T” which can initiate torsades • Long Q-T is associated with several MTT classes including: • Histone deacetylase inhibitors, multi-targeted TKIs, vascular-disrupting agents, farnesyl protein transferase (FTPase) inhibitors, Src/Abl kinase inhibitors, and protein kinase C inhibitors Mellor HR, et. al (2011). Toxicological Sciences. March 1, 2011;120(1):14-32. Molecularly Targeted Therapies March 16, 2013 l 9

  10. Long Q-T QTc prolongation (559 msec) torsade de pointes (TdP) followed by sustained TdP into ventricular fibrillation Molecularly Targeted Therapies March 16, 2013 l 10 Ayad et al, Proc (Bayl Univ Med Cent). 2010 July; 23(3): 250–255

  11. Management of Q-T Prolongation Ayad et al., 2010Proc (Bayl Univ Med Cent). 2010 July; 23(3): 250–255; ; Mellor et al, 2011; ECG= Electrocardiogram Molecularly Targeted Therapies March 16, 2013 l 11

  12. Caution When Prescribing • Select Antiarrhythmic drugs • Serotonin agonists/antagonists • Antipsychotics: phenothiazine, droperidol, haloperidol • Antidepressants: amitryptyline, clomipramine, desipramine, imipramine • Antimicrobial agents: clarithromycin, erythromycin, halofantrine, pentamidine, ketoconazole, miconazole, itraconazole • Anti-emetic agents: chlorpromazine, droperidol • Anthracyclines (doxorubicin) • Arsenic • Methadone Ayad et al., 2010Proc (Bayl Univ Med Cent). 2010 July; 23(3): 250–255; ; Mellor et al, 2011; ECG= Electrocardiogram Molecularly Targeted Therapies March 16, 2013 l 12

  13. Monitoring Left ventricular systolic dysfunction and heart failure • The diagnosis of heart failure is difficult to correlate clinically in cancer patients • Dyspnea may be due to different etiologies such as pulmonary embolism, cardiac tamponade, heart failure, or disease progression • Biomarkers such as BNP are not always accurate • Cardiomyopathy with a decrease in left ventricular (LV) ejection fraction (LVEF) can progress to heart failure (HF) and in some cases death Thomas JT, Kelly RF, Thomas SJ, et al. Am J Med 2002;112:437–45.; Burjonroppa SC, Tong AT, Xiao LC, et al.. Am J Clin Oncol 2007;30:287–93. Molecularly Targeted Therapies March 16, 2013 l 13

  14. Monitoring Left ventricular systolic dysfunction and heart failure • According to ACC/AHA guidelines for the diagnosis and management of heart failure, echocardiography is considered the single most useful diagnostic test in the evaluation of patients with heart failure • Asymptomatic decreased LV (>20%): • Modification of risk factors for coronary heart disease, lifestyle changes, and treatment of hypertension • Asymptomatic >50% decrease in LV: • ACE inhibitor, cardiology referral Jessup et al 2009 Molecularly Targeted Therapies March 16, 2013 l 14

  15. Monitoring Left ventricular systolic dysfunction and heart failure • Any Symptomatic evidence of LVEF dysfunction • Refer to cardiologist; BBlockers, ACE –I • Dobutamine stress echo to exclude CAD which could lead to CABG, angioplasty; • Consider surgical intervention for significant valvuar dysfunction if found on echocardiology • Balance co morbidities, life expectancy Jessup et al 2009 Molecularly Targeted Therapies March 16, 2013 l 15

  16. Who is at risk for pulmonary complications? • mTOR inhibitors • temsirolimus, everolimus, and ridaforolimus • Erlotinibinduced pneumonitis, and that occurs in about 1% of patients treated in the US • Bevacizumab binds to lung receptors, can cause hemoptysis • Incidence varies according to study, indication • Breast cancer, PNET, metastatic RCCa • Many MTTs are associated with pulmonary events, novel mechanism of action Molecularly Targeted Therapies March 16, 2013 l 16 Lind JSW, et al. 2012, Journal of Clinical Oncology.30(8):e104-e108; Gartrell et al, 2013; Vahid & Esmaili, 2007 Can Respir J. 2007 April; 14(3): 167–170;

  17. Patterns of Pulmonary Toxicity Other MTTs can cause pulmonary events of unclear etiology Molecularly Targeted Therapies March 16, 2013 l 17 Dimopoulou I et al. Annals of Oncology. March 2006 2006;17(3):372-379.

  18. Interventions: Pulmonary complications • Balance risk/benefit ratio with MTTs • In many cases, benefit of MTT therapy outweighs the risk of complications • Monitor lung sounds, respiratory status at every visit • Inhalers (albuterol, corticosteroid based therapy) • Smoking cessation • Prompt treatment of suspected respiratory infection • Consider drug holiday or dose reduction if cancer status warrants Molecularly Targeted Therapies March 16, 2013 l 18 Iacovelli et al.,September 2012, Vol. 51, No. 7 , Pages 873-879

  19. Conclusion • MTTs continue to be in drug development and are integral to the hope for quality of life, progression free survival • Cardiac and pulmonary adverse events are commonly seen with these classes of drugs • Knowledge as to risk of these events, prompt recognition of symptoms and intervention will benefit patients Molecularly Targeted Therapies March 16, 2013 l 19

More Related